| Name | histone deacetylase (protein family or complex) |
|---|---|
| Synonyms | Histone deacetylase; Histone deacetylases |
| Name | SMA |
|---|---|
| CAS | sodium 2-chloroacetate |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19383090 | Lunke S, El-Osta A: The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J Neurochem. 2009 Jun;109(6):1557-69. Epub 2009 Apr 4. This effect was linked to the ability of the short chain fatty acid to suppress histone deacetylase activity and activate gene transcription. |
3(0,0,0,3) | Details |
| 18537606 | Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL: Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem. 2008;15(13):1263-73. The use of HDACi and possible mechanisms of action will be reviewed in three MND, i.e. amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and spinal and bulbar muscular atrophy (SBMA), diseases among which clinical trials with HDACi are currently perfomed (ALS, SMA). |
2(0,0,0,2) | Details |
| 18971205 | Hauke J, Riessland M, Lunke S, Eyupoglu IY, Blumcke I, El-Osta A, Wirth B, Hahnen E: Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet. 2009 Jan 15;18(2):304-17. Epub 2008 Oct 29. |
2(0,0,0,2) | Details |
| 19640900 | Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2009 Oct;297(4):F996-F1005. Epub 2009 Jul 29. |
2(0,0,0,2) | Details |
| 17998807 | Gray SG, Dangond F: Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics. 2006 Apr-Jun;1(2):67-75. Epub 2006 Mar 5. |
2(0,0,0,2) | Details |
| 17889833 | Bulow R, Fitzner B, Sparmann G, Emmrich J, Liebe S, Jaster R: Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol. 2007 Dec 15;74(12):1747-57. Epub 2007 Aug 21. |
2(0,0,0,2) | Details |
| 19700647 | Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA: Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70. Epub 2009 Aug 21. |
2(0,0,0,2) | Details |
| 20097677 | Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B: SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010 Apr 15;19(8):1492-506. Epub 2010 Jan 22. Here, we analysed suberoylanilide hydroxamic acid (SAHA), a FDA-approved histone deacetylase inhibitor, as potential drug in two severe SMA mouse models each carrying two SMN2 transgenes: US-SMA mice with one SMN2 per allele (Smn (-/-);SMN2 (tg/tg)) and Taiwanese-SMA mice with two SMN2 per allele (Smn (-/-);SMN2 (tg/wt)), both on pure FVB/N background. |
1(0,0,0,1) | Details |
| 20190275 | Mende Y, Jakubik M, Riessland M, Schoenen F, Rossbach K, Kleinridders A, Kohler C, Buch T, Wirth B: Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN /Smn splicing. Hum Mol Genet. 2010 Mar 18. Correct splicing of SMN2 can be facilitated by histone deacetylase inhibitors (HDACis) via upregulation of SFRS10. |
1(0,0,0,1) | Details |
| 17610967 | Glenisson W, Castronovo V, Waltregny D: Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta. 2007 Oct;1773(10):1572-82. Epub 2007 Jun 12. Herein, we sought to investigate the role of histone deacetylases (HDAC) in TGFbeta1-induced MF differentiation. |
1(0,0,0,1) | Details |
| 19584083 | Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C, Coras R, Blumcke I, Hahnen E, Wirth B: LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to Hum Mol Genet. 2009 Oct 1;18(19):3645-58. Epub 2009 Jul 7. Histone deacetylase inhibitors (HDACi) are potential candidates for therapeutic approaches in cancer and neurodegenerative diseases such as spinal muscular atrophy (SMA)--a common autosomal recessive disorder and frequent cause of early childhood death. |
1(0,0,0,1) | Details |
| 19224893 | Wang Z, Chen C, Finger SN, Kwajah S, Jung M, Schwarz H, Swanson N, Lareu FF, Raghunath M: Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?. Eur Respir J. 2009 Jul;34(1):145-55. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. |
1(0,0,0,1) | Details |
| 17611778 | Bai X, Wu L, Liang T, Liu Z, Li J, Li D, Xie H, Yin S, Yu J, Lin Q, Zheng S: Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Jan;134(1):83-91. Epub 2007 Jul 5. METHODS: Activation of HSCs, the expression of myocyte enhancer factor 2 (MEF2), class II histone deacetylases (II HDACs) and histone acetylation were analyzed in specimens of primary HCCs, cirrhotic and normal livers. |
1(0,0,0,1) | Details |
| 19168895 | Sharma A, Mehan MM, Sinha S, Cowden JW, Mohan RR: Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2695-701. Epub 2009 Jan 24. PURPOSE: Trichostatin A (TSA), a histone deacetylase inhibitor, has been shown to suppress TGF-beta-induced fibrogenesis in many nonocular tissues. |
1(0,0,0,1) | Details |
| 18345520 | Dayangac-Erden D, Topaloglu H, Erdem-Yurter H: A preliminary report on spinal muscular atrophy lymphoblastoid cell lines: are they an appropriate tool for drug screening?. Adv Ther. 2008 Mar;25(3):274-9. METHODS: In this preliminary study, we investigated the effect of phenylbutyrate, a histone deacetylase (HDAC) inhibitor, on SMN2 expression in two SMA type III Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines to understand the suitability of lymphoblastoid cell lines in drug screening. |
1(0,0,0,1) | Details |
| 19329758 | Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruine AP, Herman JG, van Engeland M: Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis. 2009 Jun;30(6):1041-8. Epub 2009 Mar 27. Several candidate TSGs, among which methyl-CpG-binding domain protein 1 (MBD1), CpG-binding protein CXXC1, Sma- and Mad-related protein 4 (SMAD4), deleted in colon cancer (DCC) and methyl-CpG-binding domain protein 2 (MBD2) are closely linked on a 4-Mb DNA region on chromosome18q21. |
0(0,0,0,0) | Details |